Przegaliński Edmund, Gołda Anna, Frankowska Małgorzata, Zaniewska Magdalena, Filip Małgorzata
Laboratory of Drug Addiction Pharmacology, Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, 12 Smetna, Poland.
Eur J Pharmacol. 2007 Mar 22;559(2-3):165-72. doi: 10.1016/j.ejphar.2006.12.012. Epub 2007 Jan 16.
In order to substantiate the concept that cocaine behavioral effects may be influenced by serotonin (5-HT)1B receptors, male Wistar rats were trained to self-administer cocaine intravenously (0.5 mg/kg/injection), and were systemically pretreated with the selective 5-HT1B receptor antagonist N-[3-[3-(dimethylamine)ethoxy]-4-methoxyphenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-carboxamide hydrochloride (SB 216641), or with the agonist 5-propoxy-3(1,2,3,6-tetrahydro-4-pyridinyl)-1H-pyrrolo[3,2-b]pyridine hydrochloride (CP 94253) before test session during the maintenance phase. The effects of the 5-HT1B receptor ligands on a control reinforcer (food)-induced self-administration and on basal locomotor activity were also assessed. SB 216641 (2.5-7.5 mg/kg) was inactive in altering the cocaine (0.5 mg/kg/injection)-maintained responding and at the highest dose (7.5 mg/kg) it did not alter the self-administration of a cocaine dose on the descending limb of the cocaine (0.125-0.5 mg/kg/injection) dose-effect function. On the other hand, CP 94253 (2.5-7.5 mg/kg) attenuated the cocaine (0.5 mg/kg/injection)-maintained responding with a significant inhibitory effect seen at 7.5 mg/kg, while its doses of 2.5-5 mg/kg potently reduced the self-administration of cocaine (0.125-0.25 mg/kg/injection), in a manner similar to the effect produced by increasing the unit dose of cocaine. The inhibitory effects of CP 94253 (5 mg/kg) on the cocaine (0.125 or 0.25 mg/kg/injection) self-administration were blocked by SB 216641 (7.5 mg/kg). Food reinforcing potential was not altered when either SB 216641 or CP 94253 was given in a dose range between 2.5-7.5 mg/kg. Moreover, none of the 5-HT1B receptor ligands altered horizontal locomotor activity while CP 9253 significantly reduced vertical activity. Our present findings extend previous observations that tonic activation of 5-HT1B receptors is not required for cocaine reinforcement while pharmacological stimulation of 5-HT1B receptors enhances such a property of the psychostimulant. Furthermore, we demonstrated that 5-HT1B receptor agonist-induced enhancement of cocaine reward was independent of an alteration in natural reinforcement.
为了证实可卡因的行为效应可能受5-羟色胺(5-HT)1B受体影响这一概念,雄性Wistar大鼠被训练静脉内自我给药可卡因(0.5毫克/千克/注射),并在维持阶段的测试环节前,用选择性5-HT1B受体拮抗剂N-[3-[3-(二甲胺)乙氧基]-4-甲氧基苯基]-2'-甲基-4'-(5-甲基-1,2,4-恶二唑-3-基)-[1,1'-联苯]-4-甲酰胺盐酸盐(SB 216641)或激动剂5-丙氧基-3(1,2,3,6-四氢-4-吡啶基)-1H-吡咯并[3,2-b]吡啶盐酸盐(CP 94253)进行全身预处理。还评估了5-HT1B受体配体对对照强化物(食物)诱导的自我给药以及基础运动活动的影响。SB 216641(2.5 - 7.5毫克/千克)在改变可卡因(0.5毫克/千克/注射)维持的反应方面无活性,且在最高剂量(7.5毫克/千克)时,它并未改变可卡因剂量效应函数下降支上可卡因剂量(0.125 - 0.5毫克/千克/注射)的自我给药情况。另一方面,CP 94253(2.5 - 7.5毫克/千克)减弱了可卡因(0.5毫克/千克/注射)维持的反应,在7.5毫克/千克时可见显著抑制作用,而其2.5 - 5毫克/千克的剂量能有效降低可卡因(0.125 - 0.25毫克/千克/注射) 的自我给药,其方式类似于增加可卡因单位剂量所产生的效果。CP 94253(5毫克/千克)对可卡因(0.125或0.25毫克/千克/注射)自我给药的抑制作用被SB 216641(7.5毫克/千克)阻断。当SB 216641或CP 94253以2.5 - 7.5毫克/千克的剂量范围给药时,食物强化潜能未改变。此外,5-HT1B受体配体均未改变水平运动活动,而CP 9253显著降低了垂直活动。我们目前的研究结果扩展了先前的观察结果,即可卡因强化不需要5-HT1B受体的紧张性激活,而5-HT1B受体的药理刺激可增强这种精神兴奋剂的这一特性。此外,我们证明5-HT1B受体激动剂诱导的可卡因奖赏增强与自然强化的改变无关。